Monofluoroquinolones (МFQs): Safetyuseinpediatrics (Clinical, Morphological and Follow-up Data)

Sergey Postnikov; Natalia Teplova; Galina Chervyakova; Anatolyi Kamenev; Vladimir Nazhimov; Alexey Ermilin; Marya Kostyleva; Anna Gratsyanskaya

doi:doi:10.11648/j.ajp.20210704.11

Monofluoroquinolones (МFQs): Safetyuseinpediatrics (Clinical, Morphological and Follow-up Data)

Sergey Postnikov, Natalia Teplova, Galina Chervyakova, Anatolyi Kamenev, Vladimir Nazhimov, Alexey Ermilin, Marya Kostyleva, Anna Gratsyanskaya

Published in American Journal of Pediatrics (Volume 7, Issue 4)

Received: 31 August 2021 Accepted: 22 September 2021 Published: 12 October 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

2 groups of children were included to assess monofluoroquinolones (МFQs) safety in open observational prospective study: 169 cystic fibrosis patients (pulmonary exacerbation phase) and 55 aplastic anemia patients (neutropenia phase) at age 6 months to 16 years treated with ciprofloxacin (CPF), ofloxacin (OF) or pefloxacin (PF) at different time points. Study purpose was to compare МFQS tolerability (arthropathy-focused mainly) in intermittent (treatment doses 15-50 mg/kg in cystic fibrosis patients) or uninterrupted prolonged use (prophylactic doses 10-15 mg/kg in aplastic anemia patients). It was showed (accumulated data in both groups) that quinolone arthropathy (QА) had developed in 8.4% of cases mostly in PF group (74%), more frequently in cystic fibrosis patients (CF) and exclusively in adolescents with full regression and without any height impact. Absence of residual arthrological symptoms and any height impact resulted from the fact that FQs are not cumulated in cartilaginous structures in chondropathogenic concentrations, and the occurrence of QA is caused by the development of synovitis as a result of individual FQs intolerance.

Published in	American Journal of Pediatrics (Volume 7, Issue 4)
DOI	10.11648/j.ajp.20210704.11
Page(s)	182-188
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Fluoroquinolones, Arthropathy, Linear Growth, Knee Joint Morphology

References

[1]	E. U. Kataeva, N. E. Khaidartzeva, A. L. Burmistrova “Assessment of fluoroquinolones sensitivity of urine isolates E. Coli, retrieved from ambulatory patients”. Clinical microbiology and antibiotics chemotherapy, 2021, v. 23, appendix 1, p. 19.
[2]	I. A. Mamonova, I. V. Babushkina, B. Y. Ulianov, S. P. Shpinyak “Effect of antibacterial drug from the group of fluoroquinolones II generation to the biological film-forming process of St. aureus strain isolated from periprosthetic major joint infection”. Clinical microbiology and antibacterial chemotherapy, 2021, v. 23, appendix 1, p 28.
[3]	Catherine M. Hill, Jogn A. Dodge “Practical guidelines for cystic fibrosis care”. Solvey Healthcare, 1998.
[4]	V. N. Pavlova, book “Sinovial environment of joints”, 1980.
[5]	V. N. Pavlova, book “Cartilage”, Moscow, published by Medicine, 1988.
[6]	A. Pruna, A. Barka, D. Nochy et al. “Pefloxacin as a first-line treatment for nephrotic syndrome in minimal glomerular lesions in the adult”. Nephrology 1997; 18 (3): 95-101.
[7]	K-Le-Loet, C. Fessard, C. Noblet, L-A-Sait, N. Moore “Severe arthropathy in a adolescent treated with Pf”. J. Zheumatol (18, N12, 1941-42, 1991).
[8]	James E. Tisdals, Douglas A. Miller “Drug-induced diseases. Prevention, detection and management” Bethesda, eds 2018.
[9]	B. K. Romanov, Y. V. Olefir, R. N. Alyautdin et al. “Safety of medicines use in children – data from international monitoring”. Safety and risk of pharmacotherapy, 2019; 7 (2): 57-64.
[10]	N. V. Molchan, Y. A. Smirnova, N. Y. Veltz et al. “Fluoroquinolone antibiotics: safety data received from ciprofloxacin use experience”. Safety and risk of pharmacotherapy, 2019; v. 7, N2, pp. 57-64.
[11]	I. V. Shaad, J. Wedgwood-Krucko “Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity”. Infection 15 (1987); N3, p. 165-168.
[12]	Matti Nuutinen, Juna Turtinen and Matti Uhari “Growth and joints symptoms in children treated with nalidixic acid”. Pediatric infectious disease Journal, 1994; 3: 798-800, Vol. 13, N9, September.
[13]	V. P. Yakovlev, E. N. Padeyskaya, S. V. Yakovlev “Ciprofloxacin in clinical practice”, Moscow, Informelectro, 2000.
[14]	Abrar K. Tabit, Dania F. Fatani, Maryam Bamakhrama et al. “Antibiotic penetration into bone and joints: an updated review”. International journal of infectious diseases, 81 (2019) 128-136.
[15]	A. B. Zborovsky, I. N. Tyurenkov, Y. B. Belousov “Adverse drug reactions”. Medicine information agency, Moscow, 2008.
[16]	A. A. Yakovleva, M. Y. Studenikin “Children arthrology”. Moscow, published by Medicine, 1981.
[17]	Stacey E. Mills “Histolofy for pathologists” Fourth edition Wolters Kluwer /Lippincott Williams and Wilkins 2012.
[18]	Karisma Patel and Jennifer L. Goldman “Safety concerns surrounding quinolone use in children” J. clin. pharmacol. 2016 September; 56 (9): 1060-75.
[19]	Kevin Meestors, Ann M. Racs, Johan G. Vande Walle “What do I need to know about fluoroquinolones in children” Arch. dis. child. educ. pract. ed. 2018; 0: 1-5.

Cite This Article

Plain Text BibTeX RIS

APA Style

Sergey Postnikov, Natalia Teplova, Galina Chervyakova, Anatolyi Kamenev, Vladimir Nazhimov, et al. (2021). Monofluoroquinolones (МFQs): Safetyuseinpediatrics (Clinical, Morphological and Follow-up Data). American Journal of Pediatrics, 7(4), 182-188. https://doi.org/10.11648/j.ajp.20210704.11

Copy | Download

ACS Style

Sergey Postnikov; Natalia Teplova; Galina Chervyakova; Anatolyi Kamenev; Vladimir Nazhimov, et al. Monofluoroquinolones (МFQs): Safetyuseinpediatrics (Clinical, Morphological and Follow-up Data). Am. J. Pediatr. 2021, 7(4), 182-188. doi: 10.11648/j.ajp.20210704.11

Copy | Download

AMA Style

Sergey Postnikov, Natalia Teplova, Galina Chervyakova, Anatolyi Kamenev, Vladimir Nazhimov, et al. Monofluoroquinolones (МFQs): Safetyuseinpediatrics (Clinical, Morphological and Follow-up Data). Am J Pediatr. 2021;7(4):182-188. doi: 10.11648/j.ajp.20210704.11

Copy | Download

@article{10.11648/j.ajp.20210704.11,
  author = {Sergey Postnikov and Natalia Teplova and Galina Chervyakova and Anatolyi Kamenev and Vladimir Nazhimov and Alexey Ermilin and Marya Kostyleva and Anna Gratsyanskaya},
  title = {Monofluoroquinolones (МFQs): Safetyuseinpediatrics (Clinical, Morphological and Follow-up Data)},
  journal = {American Journal of Pediatrics},
  volume = {7},
  number = {4},
  pages = {182-188},
  doi = {10.11648/j.ajp.20210704.11},
  url = {https://doi.org/10.11648/j.ajp.20210704.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajp.20210704.11},
  abstract = {2 groups of children were included to assess monofluoroquinolones (МFQs) safety in open observational prospective study: 169 cystic fibrosis patients (pulmonary exacerbation phase) and 55 aplastic anemia patients (neutropenia phase) at age 6 months to 16 years treated with ciprofloxacin (CPF), ofloxacin (OF) or pefloxacin (PF) at different time points. Study purpose was to compare МFQS tolerability (arthropathy-focused mainly) in intermittent (treatment doses 15-50 mg/kg in cystic fibrosis patients) or uninterrupted prolonged use (prophylactic doses 10-15 mg/kg in aplastic anemia patients). It was showed (accumulated data in both groups) that quinolone arthropathy (QА) had developed in 8.4% of cases mostly in PF group (74%), more frequently in cystic fibrosis patients (CF) and exclusively in adolescents with full regression and without any height impact. Absence of residual arthrological symptoms and any height impact resulted from the fact that FQs are not cumulated in cartilaginous structures in chondropathogenic concentrations, and the occurrence of QA is caused by the development of synovitis as a result of individual FQs intolerance.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Monofluoroquinolones (МFQs): Safetyuseinpediatrics (Clinical, Morphological and Follow-up Data)
AU  - Sergey Postnikov
AU  - Natalia Teplova
AU  - Galina Chervyakova
AU  - Anatolyi Kamenev
AU  - Vladimir Nazhimov
AU  - Alexey Ermilin
AU  - Marya Kostyleva
AU  - Anna Gratsyanskaya
Y1  - 2021/10/12
PY  - 2021
N1  - https://doi.org/10.11648/j.ajp.20210704.11
DO  - 10.11648/j.ajp.20210704.11
T2  - American Journal of Pediatrics
JF  - American Journal of Pediatrics
JO  - American Journal of Pediatrics
SP  - 182
EP  - 188
PB  - Science Publishing Group
SN  - 2472-0909
UR  - https://doi.org/10.11648/j.ajp.20210704.11
AB  - 2 groups of children were included to assess monofluoroquinolones (МFQs) safety in open observational prospective study: 169 cystic fibrosis patients (pulmonary exacerbation phase) and 55 aplastic anemia patients (neutropenia phase) at age 6 months to 16 years treated with ciprofloxacin (CPF), ofloxacin (OF) or pefloxacin (PF) at different time points. Study purpose was to compare МFQS tolerability (arthropathy-focused mainly) in intermittent (treatment doses 15-50 mg/kg in cystic fibrosis patients) or uninterrupted prolonged use (prophylactic doses 10-15 mg/kg in aplastic anemia patients). It was showed (accumulated data in both groups) that quinolone arthropathy (QА) had developed in 8.4% of cases mostly in PF group (74%), more frequently in cystic fibrosis patients (CF) and exclusively in adolescents with full regression and without any height impact. Absence of residual arthrological symptoms and any height impact resulted from the fact that FQs are not cumulated in cartilaginous structures in chondropathogenic concentrations, and the occurrence of QA is caused by the development of synovitis as a result of individual FQs intolerance.
VL  - 7
IS  - 4
ER  -

Copy | Download

Author Information

Sergey Postnikov

Department of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation
Natalia Teplova

Department of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation
Galina Chervyakova

Department of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation
Anatolyi Kamenev

Department of Analytical Chemistry, Moscow State University Named After MV Lomonosov, Moscow, Russian Federation
Vladimir Nazhimov

Department of Morbid Anatomy, Children Clinical Hospital of Russian National Research Medical University, Moscow, Russian Federation
Alexey Ermilin

Department of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation
Marya Kostyleva

Department of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation
Anna Gratsyanskaya

Department of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Sergey Postnikov, Natalia Teplova, Galina Chervyakova, Anatolyi Kamenev, Vladimir Nazhimov, et al. (2021). Monofluoroquinolones (МFQs): Safetyuseinpediatrics (Clinical, Morphological and Follow-up Data). American Journal of Pediatrics, 7(4), 182-188. https://doi.org/10.11648/j.ajp.20210704.11

Copy | Download

ACS Style

Sergey Postnikov; Natalia Teplova; Galina Chervyakova; Anatolyi Kamenev; Vladimir Nazhimov, et al. Monofluoroquinolones (МFQs): Safetyuseinpediatrics (Clinical, Morphological and Follow-up Data). Am. J. Pediatr. 2021, 7(4), 182-188. doi: 10.11648/j.ajp.20210704.11

Copy | Download

AMA Style

Sergey Postnikov, Natalia Teplova, Galina Chervyakova, Anatolyi Kamenev, Vladimir Nazhimov, et al. Monofluoroquinolones (МFQs): Safetyuseinpediatrics (Clinical, Morphological and Follow-up Data). Am J Pediatr. 2021;7(4):182-188. doi: 10.11648/j.ajp.20210704.11

Copy | Download

@article{10.11648/j.ajp.20210704.11,
  author = {Sergey Postnikov and Natalia Teplova and Galina Chervyakova and Anatolyi Kamenev and Vladimir Nazhimov and Alexey Ermilin and Marya Kostyleva and Anna Gratsyanskaya},
  title = {Monofluoroquinolones (МFQs): Safetyuseinpediatrics (Clinical, Morphological and Follow-up Data)},
  journal = {American Journal of Pediatrics},
  volume = {7},
  number = {4},
  pages = {182-188},
  doi = {10.11648/j.ajp.20210704.11},
  url = {https://doi.org/10.11648/j.ajp.20210704.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajp.20210704.11},
  abstract = {2 groups of children were included to assess monofluoroquinolones (МFQs) safety in open observational prospective study: 169 cystic fibrosis patients (pulmonary exacerbation phase) and 55 aplastic anemia patients (neutropenia phase) at age 6 months to 16 years treated with ciprofloxacin (CPF), ofloxacin (OF) or pefloxacin (PF) at different time points. Study purpose was to compare МFQS tolerability (arthropathy-focused mainly) in intermittent (treatment doses 15-50 mg/kg in cystic fibrosis patients) or uninterrupted prolonged use (prophylactic doses 10-15 mg/kg in aplastic anemia patients). It was showed (accumulated data in both groups) that quinolone arthropathy (QА) had developed in 8.4% of cases mostly in PF group (74%), more frequently in cystic fibrosis patients (CF) and exclusively in adolescents with full regression and without any height impact. Absence of residual arthrological symptoms and any height impact resulted from the fact that FQs are not cumulated in cartilaginous structures in chondropathogenic concentrations, and the occurrence of QA is caused by the development of synovitis as a result of individual FQs intolerance.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Monofluoroquinolones (МFQs): Safetyuseinpediatrics (Clinical, Morphological and Follow-up Data)
AU  - Sergey Postnikov
AU  - Natalia Teplova
AU  - Galina Chervyakova
AU  - Anatolyi Kamenev
AU  - Vladimir Nazhimov
AU  - Alexey Ermilin
AU  - Marya Kostyleva
AU  - Anna Gratsyanskaya
Y1  - 2021/10/12
PY  - 2021
N1  - https://doi.org/10.11648/j.ajp.20210704.11
DO  - 10.11648/j.ajp.20210704.11
T2  - American Journal of Pediatrics
JF  - American Journal of Pediatrics
JO  - American Journal of Pediatrics
SP  - 182
EP  - 188
PB  - Science Publishing Group
SN  - 2472-0909
UR  - https://doi.org/10.11648/j.ajp.20210704.11
AB  - 2 groups of children were included to assess monofluoroquinolones (МFQs) safety in open observational prospective study: 169 cystic fibrosis patients (pulmonary exacerbation phase) and 55 aplastic anemia patients (neutropenia phase) at age 6 months to 16 years treated with ciprofloxacin (CPF), ofloxacin (OF) or pefloxacin (PF) at different time points. Study purpose was to compare МFQS tolerability (arthropathy-focused mainly) in intermittent (treatment doses 15-50 mg/kg in cystic fibrosis patients) or uninterrupted prolonged use (prophylactic doses 10-15 mg/kg in aplastic anemia patients). It was showed (accumulated data in both groups) that quinolone arthropathy (QА) had developed in 8.4% of cases mostly in PF group (74%), more frequently in cystic fibrosis patients (CF) and exclusively in adolescents with full regression and without any height impact. Absence of residual arthrological symptoms and any height impact resulted from the fact that FQs are not cumulated in cartilaginous structures in chondropathogenic concentrations, and the occurrence of QA is caused by the development of synovitis as a result of individual FQs intolerance.
VL  - 7
IS  - 4
ER  -

Copy | Download